BOULDER, Colo.–(BUSINESS WIRE)—- $BDSX #patientsfirst–Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the first quarter ended March 31, 2023 and provided a corporate update. “Throughout the quarter we continued to make excellent progress and I am pleased with the start to the year. Looking at our financial performance, we reported total revenue of $9.1 million for the first quarter 2023, which rep
Click here to view original post
News
O2matic’s Proprietary Technology to be Evaluated by the University of Colorado, Funded by the U.S. Department of Defense
COPENHAGEN, Denmark & AURORA, Colo.–(BUSINESS WIRE)– #SAVEO2–O2matic, a Danish medical device company focused on developing next-generation oxygen therapy and monitoring technologies, has announced that its proprietary technology is the subject of research led by Adit […]
News
GT Molecular Announces Highly Sensitive Digital PCR and Real Time qPCR Kits for hMPXV (Human Monkeypox)
dPCR Testing and Rapid NGS Services for Wastewater FORT COLLINS, Colo., July 28, 2022 /PRNewswire/ — GT Molecular, a company providing ultrasensitive PCR assays for wastewater-based epidemiology, cancer and pathogen panels has implemented a highly […]
News
New Data on Prescription Drug Prices and Inflation
Prescription drug prices lag inflation, according to new information from the Altarum November 2022 Health Sectors Economic Indicators Briefs. With inflation top of mind for policymakers at the state and federal level, the new report […]
